Short interest for Ironwood Pharmaceuticals gives investors a sense of the degree to which investors are betting on the decline of Ironwood Pharmaceuticals's stock. Short interest data is updated every two weeks.

Ironwood Pharmaceuticals Stock (NASDAQ:IRWD), Short Interest Report

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Long Ideas

News

Penny Stocks

Health Care

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

General

IART

IRWD

PACB

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March

Intraday Update

Movers

ADIL

AGFY

AMRN

ARRY

AUMN

BBWI

BCAN

BEDU

BFLY

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLUE

CMPS

COMM

CRML

CSTL

CTKB

DAVA

DUOL

ENVB

ESTA

FIGS

GRFS

GYRE

HAYW

IHRT

INDP

INSG

IONQ

LPSN

MGNI

MIST

MRSN

NARI

NTES

NWTN

OCEA

OKTA

ORIC

PSTG

PZZA

QURE

RNLX

RVNC

SCTL

SDGR

SHLS

SIDU

SNOW

STER

STKL

SWIM

TASK

VERX

VLCN

XMTR

Shares of  Butterfly Network, Inc.  (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Labs

Biotech

Ironwood Pharmaceuticals&#39; SBS-IF treatment Apraglutide&#39;s Phase 3 trial met primary endpoints, reducing PS dependency by 25.5% vs. placebo, but misses on two key secondary endpoints.

Why Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals Inc

<ul>
<li>First prospective trial of a glucagon-like peptide (GLP-2) analog in SR GI aGVHD.</li>
<li>Results up to Day 91 show that apraglutide in SR GI aGVHD was well-tolerated with an acceptable safety profile, the study&#39;s primary objective.</li>
<li>Exploratory secondary efficacy data showed lower GI tract responses maintained through Day 91 in SR GI aGVHD patients treated with apraglutide and standard of care.</li>
</ul>

Ironwood Pharmaceuticals Announces Results From Phase 2 Exploratory STARGAZE Trial of Apraglutide For Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3>Pacific Biosciences of California, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pacb#NASDAQ">PACB</a>)</h3>
<ul>
<li>On Feb. 15, Pacific Biosciences posted a narrower-than-expected quarterly loss. &quot;Our team successfully executed its goals in 2023 and launched PacBio on a trajectory this company has never seen before,&quot; said Christian Henry, President and CEO of PacBio. &quot;We continue to build solutions across the workflow, allowing our customers to further scale on HiFi, and we are encouraged to see how researchers are already making discoveries and shifting paradigms with the power and economics of Revio and the extraordinary accuracy of Onso.&quot; The company&rsquo;s stock fell around 27% over the past five days and has a <a href="https://www.benzinga.com/quote/PACB">52-week low of $4.0050 </a>.</li>
<li>RSI Value: 28.98</li>
<li>PACB Price Action: Shares of Pacific Biosciences of California fell 4% to close at $4.1750 on Wednesday.</li>
</ul>
<h3>Ironwood Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irwd#NASDAQ">IRWD</a>)</h3>
<ul>
<li>On Feb. 29, Ironwood Pharmaceuticals released topline results from its pivotal Phase 3 STARS trial of once-weekly subcutaneous apraglutide in reducing parenteral support (PS) (drugs given by routes other than the digestive tract) dependency in adult patients with short bowel syndrome with intestinal failure (SBS-IF). The company&rsquo;s stock fell around 19% over the past five days. It <a href="https://www.benzinga.com/quote/IRWD"> has a 52-week low </a> of $8.07.</li>
<li>RSI Value: 21.99</li>
<li>IRWD Price Action: Shares of Ironwood Pharmaceuticals fell 7.5% to close at $8.62 on Wednesday.</li>
</ul>
<h3>Integra LifeSciences Holdings Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iart#NASDAQ">IART</a>)</h3>
<ul>
<li>On Feb. 28, Integra Lifesciences posted downbeat quarterly results. The company&rsquo;s stock fell around 8% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/IART"> low of $33.44.</a></li>
<li>RSI Value: 28.88</li>
<li>IART Price Action: Shares of Integra LifeSciences fell 1.2% to close at $36.11 on Wednesday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/24/03/37527629/kroger-broadcom-and-3-stocks-to-watch-heading-into-thursday"> Kroger, Broadcom And 3 Stocks To Watch Heading Into Thursday </a>

Wells Fargo analyst Mohit Bansal maintains Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) with a Overweight and lowers the price target from $20 to $14.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Ironwood Pharmaceuticals, Lowers Price Target to $14

Shares of Butterfly Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NASDAQ">BFLY</a>) fell sharply during Thursday&rsquo;s session after the company reported mixed fourth-quarter financial results.
Butterfly Network posted GAAP loss of 21 cents per share versus market estimates for a loss of 14 cents per share. The company&rsquo;s quarterly sales came in at sales came in $16.52 million versus estimates of $15.35 million.
Butterfly Network shares dipped 21.7% to $1.1588 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Enveric Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/envb#NASDAQ">ENVB</a>) gained 177.1% to $2.30 after the company announced it has signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of compounds.</li>
<li>Societal CDMO, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sctl#NASDAQ">SCTL</a>) shares climbed 132.7% to $1.07 as the company agreed to be acquired by CoreRx, Inc.</li>
<li>Volcon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlcn#NASDAQ">VLCN</a>) gained 55.4% to $1.8802 after surging around 39% on Wednesday.</li>
<li>Sidus Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sidu#NASDAQ">SIDU</a>) climbed 39.7% to $7.78.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) gained 36.4% to $2.1008. Ocean Biomedical announced joint venture partner, Virion Therapeutics to present clinical study data at 2024 APASL Global Liver Meeting.</li>
<li>Inseego Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/insg#NASDAQ">INSG</a>) rose 34.5% to $3.00.</li>
<li>Vertex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verx#NASDAQ">VERX</a>) jumped 29.8% to $32.97 after the company reported better-than-expected fourth-quarter results and issued strong FY24 guidance.</li>
<li>iHeartMedia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ihrt#NASDAQ">IHRT</a>) rose 29.1% to $2.93 following fourth-quarter results.</li>
<li>Agrify Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agfy#NASDAQ">AGFY</a>) gained 27% to $0.6161. Agrify announced a $3.4 million sales order from New Jersey woman-owned business HarvestWorks Farm.</li>
<li>Renalytix Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnlx#NASDAQ">RNLX</a>) climbed 26.5% to $1.05 after the company announced that effective Mar. 1, the US approved adding the company&#39;s kidneyintelX.dkd to its 10-year Governmentwide Acquisition Contract.</li>
<li>Tutor Perini Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tpc#NYSE">TPC</a>) gained 26% to $11.64 following fourth-quarter results.</li>
<li>Bright Scholar Education Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bedu#NYSE">BEDU</a>) gained 25.3% to $2.3178.</li>
<li>C3.ai, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ai#NYSE">AI</a>) shares rose 24.6% to $37.00 after the company reported better-than-expected third-quarter financial results.</li>
<li>Sterling Check Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ster#NASDAQ">STER</a>) jumped 24.6% to $15.49 after the company agreed to be acquired by First Advantage for approximately $2.2 billion, including outstanding debt.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) gained 24% to $2.00. Adial Pharmaceuticals was awarded a new patent covering AD04 for the potential treatment of opioid use disorder.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) jumped 24% to $7.02 after the company reported better-than-expected quarterly financial results.</li>
<li>Latham Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swim#NASDAQ">SWIM</a>) climbed 22.8% to $3.36.</li>
<li>Avidity Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rna#NASDAQ">RNA</a>) jumped 22.5% to $18.70. Avidity Biosciences announced an oversubscribed $400 million private placement.</li>
<li>Pure Storage, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pstg#NYSE">PSTG</a>) rose 21.9% to $51.35 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance above estimates. Also, UBS maintained a Neutral rating on the stock and raised its price target from $38 to $44.</li>
<li>Duolingo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/duol#NASDAQ">DUOL</a>) gained 21.6% to $237.82 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>Okta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/okta#NASDAQ">OKTA</a>) shares rose 19.8% to $104.55 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>Mersana Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrsn#NASDAQ">MRSN</a>) gained 19.5% to $5.80 after the company reported fourth-quarter financial results.</li>
<li>Establishment Labs Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/esta#NASDAQ">ESTA</a>) rose 17.8% to $45.31 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Montrose Environmental Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/meg#NYSE">MEG</a>) gained 16.7% to $38.52 following quarterly results.</li>
<li>ORIC Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oric#NASDAQ">ORIC</a>) climbed 16.1% to $13.65.</li>
<li>SunOpta Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stkl#NASDAQ">STKL</a>) rose 15% to $6.91 following strong quarterly results.</li>
<li>TaskUs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/task#NASDAQ">TASK</a>) gained 14.4% to $14.17 following upbeat quarterly results.</li>
<li>Magnite, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgni#NASDAQ">MGNI</a>) rose 13.8% to $11.93 following strong quarterly results.</li>
<li>Indaptus Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/indp#NASDAQ">INDP</a>) rose 13.8% to $2.23.</li>
<li>Hayward Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hayw#NASDAQ">HAYW</a>) gained 13.7% to $14.88 following upbeat results.</li>
<li>Hormel Foods Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hrl#NYSE">HRL</a>) rose 12.8% to $34.81 after the company reported better-than-expected first-quarter earnings and reaffirmed FY24 outlook.</li>
<li>Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) shares rose 9.2% to $0.7750. Nxu said it fully regained compliance with Nasdaq&#39;s continued listing requirements.</li>
<li>NFT Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mi#NYSE">MI</a>) shares jumped 7.9% to $0.2374.</li>
<li>Sprinklr, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cxm#NYSE">CXM</a>) gained 7.9% to $13.56. Sprinklr will replace Veradigm in S&amp;P SmallCap 600 effective prior to opening of trading on March 4, 2024.</li>
<li>Papa John&#39;s International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pzza#NASDAQ">PZZA</a>) climbed 6.8% to $74.89 following strong quarterly earnings.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>J-Long Group Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jl#NYSE">JL</a>) fell 46.3% to $6.86. J-Long Group declared a special cash dividend in aggregate amount of $6 million.</li>
<li>Golden Minerals Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aumn#NYSE">AUMN</a>) dipped 40.4% to $0.3163. Golden Minerals announced that it has elected to stop operations at its Velarde&ntilde;a Properties, located in Durango State, Mexico.</li>
<li>LivePerson, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lpsn#NASDAQ">LPSN</a>) shares declined 40% to $1.43 following fourth-quarter financial results.</li>
<li>NWTN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nwtn#NASDAQ">NWTN</a>) fell 40% to $2.99.</li>
<li>Endava plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dava#NYSE">DAVA</a>) fell 40% to $38.31 following second-quarter earnings.</li>
<li>Kineta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ka#NASDAQ">KA</a>) fell 39.7% to $1.3801 as the company announced intention to explore strategic alternatives.</li>
<li>Ironwood Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irwd#NASDAQ">IRWD</a>) fell 39% to $9.23 after the company&#39;s Phase 3 trial of once-weekly subcutaneous apraglutide did not meet two out of four key secondary endpoints.</li>
<li>Xometry, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xmtr#NASDAQ">XMTR</a>) fell 37.4% to $18.84 after the company reported fiscal fourth-quarter results and issued first-quarter guidance below estimates and disclosed a CFO transition.</li>
<li>Grifols, S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NYSE">GRFS</a>) fell 36.7% to $5.91.</li>
<li>The Chemours Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cc#NYSE">CC</a>) shares declined 33.7% to $19.05. Chemours Company named Denise Dignam as the interim CEO and Matt Abbott as the interim CFO. The company also issued preliminary 2023 results.</li>
<li>Bakkt Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bkkt#NASDAQ">BKKT</a>) fell 33.4% to $0.6792 after the company announced two securities purchase agreements.</li>
<li>CommScope Holding Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/comm#NASDAQ">COMM</a>) dipped 30% to $1.2950 after the company reported financial fourth-quarter results below estimates.</li>
<li>Critical Metals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crml#NASDAQ">CRML</a>) fell 25.2% to $11.43.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) dropped 22% to $19.34.</li>
<li>Lotus Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lot#NASDAQ">LOT</a>) fell 21.8% to $7.71.</li>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) shares fell 20.2% to $0.1621. BYND Cannasoft is entering into production agreements for its EZ-G Device.</li>
<li>Snowflake Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snow#NYSE">SNOW</a>) shares tumbled 20.1% to $183.81. Snowflake reported upbeat earnings for its fourth quarter. The company said CEO Frank Slootman has decided to retire from his role as CEO but will continue to serve as chairman of the board. Sridhar Ramaswamy has been appointed as CEO and a member of the board, effective immediately.</li>
<li>Schr&ouml;dinger, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sdgr#NASDAQ">SDGR</a>) shares declined 19.9% to $25.12 after the company reported mixed fourth-quarter financial results.</li>
<li>Castle Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cstl#NASDAQ">CSTL</a>) fell 18.7% to $19.83 following fourth-quarter financial results.</li>
<li>bluebird bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blue#NASDAQ">BLUE</a>) fell 18.2% to $1.3750.</li>
<li>Inari Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nari#NASDAQ">NARI</a>) shares fell 18.1% to $47.50 after posting a loss for the fourth quarter.</li>
<li>WW International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ww#NASDAQ">WW</a>) fell 17.9% to $3.1350 after the company reported fourth-quarter financial results and announced that director Oprah Winfrey has decided not to stand for re-election at the company&#39;s upcoming annual meeting of shareholders.</li>
<li>uniQure N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qure#NASDAQ">QURE</a>) fell 16.7% to $5.57. Goldman Sachs analyst Salveen Richter downgraded uniQure from Buy to Neutral and lowered the price target from $63 to $8.</li>
<li>Amarin Corporation plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amrn#NASDAQ">AMRN</a>) fell 16.7% to $1.09 following quarterly results.</li>
<li>DoubleVerify Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dv#NYSE">DV</a>) declined 16.6% to $32.71 after the company reported fourth quarter financial results.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shls#NASDAQ">SHLS</a>) shares dipped 16.3% to $12.89 after the company reported worse-than-expected fourth-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Milestone Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mist#NASDAQ">MIST</a>) shares fell 16% to $1.7897 after announcing a proposed public offering of common shares and pre-funded warrants.</li>
<li>COMPASS Pathways plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmps#NASDAQ">CMPS</a>) fell 16% to $10.40 following a wider-than-expected quarterly loss.</li>
<li>FIGS, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/figs#NYSE">FIGS</a>) shares fell 15.4% to $5.10 after the company reported mixed quarterly financial results.</li>
<li>The Lion Electric Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lev#NYSE">LEV</a>) dipped 12.6% to $1.46 following fourth quarter financial results.</li>
<li>Cytek Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctkb#NASDAQ">CTKB</a>) fell 12.2% to $7.67 following fourth quarter financial results.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>) shares fell 11.1% to $4.4350 following quarterly results.</li>
<li>Titan International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/twi#NYSE">TWI</a>) fell 10% to $12.73 following weak sales.</li>
<li>IonQ, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ionq#NYSE">IONQ</a>) shares declined 7.2% to $10.45 after the company reported mixed fourth quarter financial results.</li>
<li>Array Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arry#NASDAQ">ARRY</a>) fell 5.8% to $13.27.</li>
<li>Bath &amp; Body Works, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbwi#NASDAQ">BBWI</a>) fell 5.2% to $45.80 after the company reported fourth-quarter earnings and issued worse-than-expected FY24 outlook. It also authorized $500 million stock buyback.</li>
<li>NetEase, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntes#NASDAQ">NTES</a>) shares fell 3.7% to $108.03 after the company reported financial fourth-quarter results below estimates.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/02/37390717/nvidia-to-rally-around-27-here-are-10-top-analyst-forecasts-for-thursday"> NVIDIA To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday</a>

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Societal CDMO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCTL#NASDAQ">SCTL</a>) stock rose 132.6% to $1.07 during Thursday's regular session. The company's market cap stands at $112.1 million. </li>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) shares increased by 132.25% to $1.93. The market value of their outstanding shares is at $5.2 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock rose 47.29% to $5.17. The market value of their outstanding shares is at $101.0 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares moved upwards by 30.39% to $1.63. The market value of their outstanding shares is at $2.3 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock moved upwards by 29.68% to $7.34. The company's market cap stands at $644.5 million. The company's, Q4 earnings came out yesterday. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares increased by 28.91% to $1.07. The company's market cap stands at $53.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Kineta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) shares fell 42.5% to $1.3 during Thursday's regular session. The market value of their outstanding shares is at $13.5 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock fell 39.89% to $9.09. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares declined by 27.63% to $6.76. The company's market cap stands at $4.5 billion. </li>
<li>Ampio Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMPE#AMEX">AMPE</a>) shares fell 24.35% to $1.74. The market value of their outstanding shares is at $1.9 million. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) shares fell 22.37% to $19.25. The company's market cap stands at $1.6 billion. </li>
<li>Castle Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) stock fell 20.85% to $19.3. The market value of their outstanding shares is at $519.5 million. As per the press release, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMPE

Envoy Medical, Inc. - Class A Common Stock

COCH

TIVC

12 Health Care Stocks Moving In Thursday's Intraday Session

Ironwood Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) released topline results from its pivotal Phase 3 STARS trial of once-weekly subcutaneous apraglutide in reducing parenteral support (PS) (drugs given by routes other than the digestive tract) dependency in adult patients with short bowel syndrome&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/b37387326/ironwood-pharmaceuticals-announces-positive-topline-results-from-global-phase-iii-trial-of-once-we" rel="noreferrer noopener">with intestinal failure (SBS-IF)</a>.&nbsp;
SBS-IF, a rare and severe organ failure condition in which patients are dependent on PS, affects an estimated 18,000 adult patients in the U.S., Europe, and Japan.&nbsp;
The trial met its primary endpoint of relative change from baseline in actual weekly PS volume at week 24, comparing apraglutide versus placebo (-25.5% vs. -12.5%).
In addition, there were four key secondary endpoints evaluated in statistical hierarchy.&nbsp;
Apraglutide demonstrated statistical significance for the first two key secondary endpoints, with more patients in the combined population achieving at least one day/week off PS relative to baseline at week 24 versus placebo (43.0% vs. 27.5%; p=0.040) and more patients treated with apraglutide versus placebo demonstrating improvement in relative change from baseline in actual weekly PS volume at week 24 in the stoma population (-25.6% vs. -7.8%; p&lt;0.001).&nbsp;
The third and fourth key secondary endpoints were specific to colon-in-continuity patients in assessing at least one day/week off PS versus baseline and reaching enteral autonomy at week 48, which were not achieved.&nbsp;
Probably, shares tanked because of this endpoint miss.
Apraglutide was numerically favorable but not statistically significant relative to placebo for improving days off PS (51.8% versus 44.4%) and reaching enteral autonomy in seven out of 56 (12.5%) patients versus two out of 27 (7.4%) patients on placebo. Apraglutide was generally well-tolerated.
Ironwood Pharmaceuticals added apraglutide to its portfolio when it acquired VectivBio for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of approximately $1 billion,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/05/32512071/ironwood-scoops-up-gastrointestinal-diseases-player-for-1b" rel="noreferrer noopener">net of VectivBio cash and debt</a>.
Ironwood plans to submit a new drug application and other regulatory filings for apraglutide for use in adult patients with SBS who are dependent on PS.&nbsp;
Ironwood looks forward to presenting additional data from the STARS study at upcoming medical conferences later this year.
Price Action: IRWD shares are down 39.50% at $9.15 on the last check Thursday.
Photo by hans-reniers for Unsplash

WIIM

Ironwood Pharmaceuticals shares are trading lower after the company's Phase 3 trial of once-weekly subcutaneous apraglutide did not meet two out of four key secondary endpoints.

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday.
Following the market opening Thursday, the Dow traded down 0.07% to 38,923.11 while the NASDAQ rose 0.65% to 16,051.57. The S&amp;P 500 also rose, gaining, 0.30% to 5,084.74.
Check This Out: <a href="https://www.benzinga.com/news/24/02/37361652/robinhood-shake-shack-and-2-other-stocks-insiders-are-selling"> Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Communication services shares rose by 0.9% on Thursday.
In trading on Thursday, health care shares fell by 0.6%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
The annual PCE inflation rate eased slightly from 2.6% in December 2023 to 2.4% in January 2024. Excluding energy and food, the core PCE index saw a year-on-year surge of 2.8%, down from the 2.9% rate seen December and in line with the expected decrease to 2.8%.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Societal CDMO, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sctl#NASDAQ">SCTL</a>) shares shot up 132% to $1.0686. Privately held CoreRx Inc. will acquire Societal CDMO, a contract development and manufacturing organization.
Shares of Enveric Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/envb#NASDAQ">ENVB</a>) got a boost, surging 130% to $1.91. Enveric Biosciences signed a non-binding term sheets to pursue the exclusive out-licensing of three classes of compounds.
Volcon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlcn#NASDAQ">VLCN</a>) shares were also up, gaining 58% to $1.9101 after surging around 39% on Wednesday.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
LivePerson, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lpsn#NASDAQ">LPSN</a>) shares dropped 40% to $1.4395 following fourth-quarter financial results.
Shares of The Chemours Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cc#NYSE">CC</a>) were down 40% to $17.20 after the company announced executive changes and said it is delaying its fourth quarter results and 10-K.
Ironwood Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irwd#NASDAQ">IRWD</a>) was down, falling 39% to $9.19 after the company announced topline results from global Phase III trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF).
Also Check This Out:<a href="https://www.benzinga.com/news/24/02/37334066/top-3-energy-stocks-that-could-sink-your-portfolio-in-q1"> Top 3 Energy Stocks That Could Sink Your Portfolio In Q1 </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.4% to $78.23 while gold traded up 0.6% at $2,055.70.
Silver traded rose 0.9% to $22.84 on Thursday while copper rose 0.4% to $3.8540.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mixed today. The eurozone&rsquo;s STOXX 600 rose 0.2%, London&rsquo;s FTSE 100 rose 0.3% while Spain&rsquo;s IBEX 35 Index fell 0.4% The German DAX gained 0.6% French CAC 40 fell 0.1% while Italy&rsquo;s FTSE MIB Index declined 0.1%.
German jobless rate held came in unchanged at 5.9% in February, while German retail sales fell by 0.4% month-over-month in January. Spanish annual consumer price inflation rate declined to a six-month low level of 2.8% in February.
French economy expanded 0.1% on quarter in the fourth quarter. The annual inflation rate in France eased to 2.9% in February, while producer prices declined 1.3% month-over-month in January.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mixed on Thursday, with Japan&rsquo;s Nikkei 225 falling 0.11%, Hong Kong&rsquo;s Hang Seng Index falling 0.15%, China&rsquo;s Shanghai Composite Index gaining 1.94% and India&rsquo;s S&amp;P BSE Sensex gaining 0.27%.
Indian fiscal deficit shrank to INR 11.03 trillion in April-January compared to INR 11.91 trillion in the year-ago period. Japanese housing starts fell by 7.5% year-over-year in January following a 4.0% decline in the previous month. Retail sales in Japan gained 2.3% year-over-year in January.
&nbsp;
<h3>Economics</h3>
&nbsp;
The annual PCE inflation rate eased slightly from 2.6% in December 2023 to 2.4% in January 2024. Excluding energy and food, the core PCE index saw a year-on-year surge of 2.8%, down from the 2.9% rate seen December and in line with the expected decrease to 2.8%.
Personal spending rose by 0.2% from the previous month, while personal income rose by 1%.
U.S. initial jobless claims rose by 13,000 to 215,000 in the week ending Feb. 24.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37356403/cramer-says-this-ai-stock-is-just-an-nvidia-play-prefers-this-stock-over-anheuser-busch"> Cramer Says This AI Stock Is Just An Nvidia Play, Prefers This Stock Over Anheuser-Busch </a>
&nbsp;

Earnings

Eurozone

Commodities

Global

Nasdaq Gains 100 Points Following PCE Data

Thursday&#8217;s premarket trading session saw substantial upward momentum propelled by major tech stocks, laying the groundwork for a promising session for <a href="https://www.benzinga.com/markets">U.S. equity indices</a>.
This surge comes as the Fed&#8217;s preferred measure of inflation meets anticipated levels from last month, thereby failing to disrupt expectations of potential interest rate cuts in the <a href="https://www.benzinga.com/news/econ-s/24/02/37392512/feds-preferred-inflation-gauge-matches-expectations-personal-income-soars-thursdays-economic-digest">first half of the year.</a>
Futures on the Nasdaq 100 Index edged up 0.6% to 18,000 points at 8:50 a.m. in New York, poised to fully recover Wednesday&#8217;s losses, according to data from the <a href="https://pro.benzinga.com/dashboard">Benzinga Pro platform</a>. 
Contracts on the S&amp;P 500 rose 0.4% to 5,090 points, reaching levels last observed at the beginning of the week.
The Dow Jones, which has limited exposure to tech stocks, saw only a marginal increase of 0.1%.
The most significant reaction was seen in small-cap stocks, with contracts on the Russell 2000 index, as tracked by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), surging by 1.6%.
Yields on Treasury bonds fell, with the 10-year benchmark yield dropping to 4.25%. Market-implied probabilities on a Fed rate cut by June inched higher to 67%, up from Wednesday&#8217;s 62%. 
The U.S. Dollar Index (DXY), as monitored through the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), declined by 0.2% following the inflation data. 
<h3 class="wp-block-heading">Mega-Cap Stock Movers Premarket Thursday</h3>
<h4 class="wp-block-heading">Top Gainers</h4>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg</td>
<td>Chg %</td>
</tr>
<tr>
<td>Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)</td>
<td>606.20</td>
<td>9.72</td>
<td>1.63%</td>
</tr>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>1,310.00</td>
<td>20.58</td>
<td>1.60%</td>
</tr>
<tr>
<td>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>787.23</td>
<td>10.60</td>
<td>1.36%</td>
</tr>
<tr>
<td>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</td>
<td>178.74</td>
<td>2.20</td>
<td>1.25%</td>
</tr>
<tr>
<td>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>204.43</td>
<td>2.39</td>
<td>1.18%</td>
</tr>
</tbody>
</table>
</figure>
<h4 class="wp-block-heading">Worst Performers</h4>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg</td>
<td>Chg %</td>
</tr>
<tr>
<td>PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>)</td>
<td>166.00</td>
<td>-1.03</td>
<td>-0.62%</td>
</tr>
<tr>
<td>McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>)</td>
<td>293.52</td>
<td>-1.67</td>
<td>-0.57%</td>
</tr>
<tr>
<td>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)</td>
<td>206.17</td>
<td>-0.83</td>
<td>-0.40%</td>
</tr>
<tr>
<td>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>)</td>
<td>196.85</td>
<td>-0.72</td>
<td>-0.36%</td>
</tr>
<tr>
<td>Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)</td>
<td>54.90</td>
<td>-0.20</td>
<td>-0.36%</td>
</tr>
<tr>
<td>Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>)</td>
<td>162.50</td>
<td>-0.54</td>
<td>-0.33%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500 Movers Premarket Thursday</h3>
<h4 class="wp-block-heading">Top Gainers</h4>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg</td>
<td>Chg %</td>
</tr>
<tr>
<td>Hormel Foods Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRL#NYSE">HRL</a>)</td>
<td>33.13</td>
<td>2.30</td>
<td>7.46%</td>
</tr>
<tr>
<td>Monster Beverage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>)</td>
<td>58.40</td>
<td>2.55</td>
<td>4.57%</td>
</tr>
<tr>
<td>Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)</td>
<td>83.02</td>
<td>3.34</td>
<td>4.19%</td>
</tr>
<tr>
<td>Enphase Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NYSE">ENPH</a>)</td>
<td>123.89</td>
<td>4.79</td>
<td>4.02%</td>
</tr>
<tr>
<td>Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>137.28</td>
<td>5.22</td>
<td>3.95%</td>
</tr>
</tbody>
</table>
</figure>
<h4 class="wp-block-heading">Worst Performers</h4>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg</td>
<td>Chg %</td>
</tr>
<tr>
<td>Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>)</td>
<td>44.80</td>
<td>-3.53</td>
<td>-7.30%</td>
</tr>
<tr>
<td>NiSource Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NI#NYSE">NI</a>)</td>
<td>25.32</td>
<td>-0.53</td>
<td>-2.03%</td>
</tr>
<tr>
<td>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>)</td>
<td>28.16</td>
<td>-0.56</td>
<td>-1.95%</td>
</tr>
<tr>
<td>CF Industries Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>)</td>
<td>78.64</td>
<td>-1.26</td>
<td>-1.58%</td>
</tr>
<tr>
<td>Dominion Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>)</td>
<td>47.59</td>
<td>-0.76</td>
<td>-1.57%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Russell 2000 Movers Premarket Thursday</h3>
<h4 class="wp-block-heading">Top Gainers</h4>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg</td>
<td>Chg %</td>
</tr>
<tr>
<td>The Children&#8217;s Place, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>)</td>
<td>24.98</td>
<td>5.78</td>
<td>30.10%</td>
</tr>
<tr>
<td>Sterling Check Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STER#NASDAQ">STER</a>)</td>
<td>15.61</td>
<td>3.19</td>
<td>25.72%</td>
</tr>
<tr>
<td>Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>)</td>
<td>18.49</td>
<td>3.23</td>
<td>21.17%</td>
</tr>
<tr>
<td>Voyager Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>)</td>
<td>10.85</td>
<td>1.88</td>
<td>20.96%</td>
</tr>
<tr>
<td>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>)</td>
<td>235.90</td>
<td>40.39</td>
<td>20.66%</td>
</tr>
<tr>
<td>C3.ai, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AI#NASDAQ">AI</a>)</td>
<td>35.28</td>
<td>5.59</td>
<td>18.83%</td>
</tr>
</tbody>
</table>
</figure>
Worst Performers
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg</td>
<td>Chg %</td>
</tr>
<tr>
<td>Ironwood Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>)</td>
<td>10.59</td>
<td>-4.53</td>
<td>-29.96%</td>
</tr>
<tr>
<td>Xometry, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>)</td>
<td>21.50</td>
<td>-8.59</td>
<td>-28.55%</td>
</tr>
<tr>
<td>WW International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>)</td>
<td>2.83</td>
<td>-0.98</td>
<td>-25.82%</td>
</tr>
<tr>
<td>Butterfly Network, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>)</td>
<td>1.19</td>
<td>-0.29</td>
<td>-19.59%</td>
</tr>
<tr>
<td>LivePerson, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>)</td>
<td>1.93</td>
<td>-0.47</td>
<td>-19.58%</td>
</tr>
<tr>
<td>FIGS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>)</td>
<td>5.00</td>
<td>-1.03</td>
<td>-17.08%</td>
</tr>
</tbody>
</table>
</figure>
Read now: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37377354/american-express-hits-all-time-high-chart-points-to-upcoming-bull-battle-at-resista">American Express Hits All-Time High: Chart Points To Upcoming Bull Battle At Resistance Line</a>
Wall Street bull illustration created using artificial intelligence via MidJourney.

Equities

Large Cap

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Currency ETFs

Econ #s

Economics

Federal Reserve

Tech

ETFs

AVGO

ENPH

MNST

NFLX

NVDA

PLCE

TSLA

PowerShares DB US Dollar Index Bullish Fund

VYGR

Tech Stocks Set To Rise Thursday As January Inflation Data Fails To Scare Markets, Small Caps Surge

<h3>Gainers</h3>
<ul>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) stock rose 162.3% to $2.18 during Thursday's pre-market session. The company's market cap stands at $5.9 million. </li>
<li>Societal CDMO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCTL#NASDAQ">SCTL</a>) shares moved upwards by 134.78% to $1.08. The company's market cap stands at $113.1 million. </li>
<li>NeuroBo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRBO#NASDAQ">NRBO</a>) shares increased by 45.11% to $7.43. The company's market cap stands at $36.4 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock moved upwards by 28.97% to $0.89. The market value of their outstanding shares is at $28.7 million. </li>
<li>Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) stock increased by 21.91% to $46.89. The market value of their outstanding shares is at $1.2 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) shares moved upwards by 20.64% to $18.41. The market value of their outstanding shares is at $1.4 billion. As per the press release, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) shares decreased by 27.7% to $10.94 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. </li>
<li>Milestone Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) stock fell 20.19% to $1.7. The market value of their outstanding shares is at $56.9 million. </li>
<li>Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) stock fell 14.19% to $1.27. The company's market cap stands at $263.0 million. The company's, Q4 earnings came out yesterday. </li>
<li>Schrodinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) stock fell 13.3% to $27.2. The market value of their outstanding shares is at $1.9 billion. The company's, Q4 earnings came out yesterday. </li>
<li>ClearPoint Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) shares declined by 13.22% to $6.7. The company's market cap stands at $164.9 million. </li>
<li>Ampio Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMPE#AMEX">AMPE</a>) stock fell 13.05% to $2.0. The market value of their outstanding shares is at $2.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLPT

NRBO

ONMD

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Apraglutide met the primary endpoint of relative change from baseline in actual weekly parenteral support (PS) volume at week 24, driven by both stoma and colon-in-continuity populations &ndash;
&ndash; Apraglutide also showed a clinically meaningful improvement at week 24, with patients achieving at least one day off PS per week &ndash;
&ndash; Apraglutide was generally well-tolerated, and the safety profile was consistent with previously-reported studies of apraglutide in this patient population &ndash;
&ndash; Ironwood to submit new drug application and other regulatory filings for apraglutide as a once-weekly GLP-2 analog for use in adult patients with SBS who are dependent on PS &ndash;

Ironwood Pharmaceuticals Announced Topline Results From Its Pivotal Phase 3 STARS Trial Of Once-weekly Subcutaneous Apraglutide In Reducing Parenteral Support Dependency In Adult Patients With Short Bowel Syndrome With Intestinal Failure

As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major overbought players in this sector.
<h3>Solid Biosciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sldb#NASDAQ">SLDB</a>)</h3>
<ul>
<li>On Jan. 16, Solid Biosciences said it was granted FDA Orphan drug designation for duchenne muscular dystrophy gene therapy candidate SGT-003. The company&rsquo;s stock gained around 19% over the past five days and has a <a href="https://www.benzinga.com/quote/SLDB">52-week high of $9.40 </a>.</li>
<li>RSI Value: 70.55</li>
<li>SLDB Price Action: Shares of Solid Biosciences gained 16.6% to close at $9.15 on Wednesday.</li>
</ul>
<h3>Lexicon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxrx#NASDAQ">LXRX</a>)</h3>
<ul>
<li>On Jan. 8, Lexicon Pharmaceuticals announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference. The company&rsquo;s stock gained around 152% over the past month and <a href="https://www.benzinga.com/quote/LXRX"> has a 52-week high </a> of $3.79.</li>
<li>RSI Value: 87.00</li>
<li>LXRX Price Action: Shares of Lexicon Pharmaceuticals gained 13.3% to close at $3.32 on Wednesday.</li>
</ul>
<h3>Ironwood Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irwd#NASDAQ">IRWD</a>)</h3>
<ul>
<li>On Jan. 17, Craig-Hallum analyst Chase Knickerbocker initiated coverage on Ironwood Pharmaceuticals with a Buy rating and announced a price target of $21. The company&rsquo;s stock gained around 32% over the past month and has a <a href="https://www.benzinga.com/quote/IRWD"> 52-week high </a> of $15.70.</li>
<li>RSI Value: 81.79</li>
<li>IRWD Price Action: Shares of Ironwood Pharmaceuticals gained 1.6% to close at $15.45 on Wednesday.</li>
</ul>
<h3>Dyne Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dyn#NASDAQ">DYN</a>)</h3>
<ul>
<li>On Jan. 3, Dyne Therapeutics announced initial clinical data from its ACHIEVE trial of DYNE-101 in patients with DM1 and its DELIVER trial of DYNE-251 in patients with DMD.. The company&rsquo;s stock jumped around 45% over the past month and has a 52-week high is $25.50.</li>
<li>RSI Value: 71.46</li>
<li>DYN Price Action: Shares of Dyne Therapeutics gained 4.7% to close at $24.19 on Wednesday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/24/02/37149816/cisco-deere-and-3-stocks-to-watch-heading-into-thursday"> Cisco, Deere And 3 Stocks To Watch Heading Into Thursday </a>
&nbsp;

Short Ideas

LXRX

SLDB

Top 4 Health Care Stocks You May Want To Dump In February

Guidance

Ironwood Pharmaceuticals Expects FY24 Sales Between $435M-$455M Vs. 462.82M Estimate; Sees FY24 Adjusted EBITDA Above $150M

Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) reported quarterly sales of $117.55 million which beat the analyst consensus estimate of $117.48 million by 0.06 percent. This is a 9.66 percent increase over sales of $107.20 million the same period last year.

Ironwood Pharmaceuticals Q4 Sales $117.55M Beat $117.48M Estimate, Generated $35.8M In Cash From Operations In Q4

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Ironwood Pharmaceuticals Stock (NASDAQ:IRWD), Short Interest Report

People Also Watch